TY  - CHAP
AU  - Kazuhiko Hayashi
AU  - Masatoshi Ishigami
AU  - Yoji Ishizu
AU  - Teiji Kuzuya
AU  - 
Takashi Honda
AU  - Yoshihiko Tachi
AU  - Tetsuya Ishikawa
AU  - Yoshiaki Katano
AU  - 
Kentaro Yoshioka
AU  - Hidenori Toyoda
AU  - Takashi Kumada
AU  - Hidemi Goto
and Yoshiki Hirooka
ED  - Martina Smolic
ED  - Aleksandar Vcev
ED  - George Y. Wu
Y1  - 2017-10-04
PY  - 2017
T1  - Impact of HBV Infection on Outcomes of Direct-Acting Antiviral Therapy of Chronic Hepatitis C
N2  - In the past few years, remarkable progress has been made in our understanding of HCV biology, pathogenesis of infection, and structure-function relationships. This has led to quantum advances in clinical efficacy and tolerability. Yet, in spite of this amazing progress, there remain obstacles to widespread successful treatment. These issues include biological failures even with direct-acting agents, lack of options for individual with organ failures, drug-drug interactions, access to medications either due to lack of availability or affordability, and psychiatric and social issues. These problems are likely to remain in the future. Therefore, this book has been created by distinguished faculties from around the world to address the progress in our understanding of HCV infection and to review new treatment options, limitations, and accessibility of new therapeutic options.
BT  - Update on Hepatitis C
SP  - Ch. 4
UR  - https://doi.org/10.5772/intechopen.70436
DO  - 10.5772/intechopen.70436
SN  - 978-953-51-3564-7
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-27
ER  -